<i>MCC</i> Gene Silencing Is a CpG Island Methylator Phenotype-Associated Factor That Predisposes Colon Cancer Cells to Irinotecan and Olaparib

<i>MCC</i> Gene Silencing Is a CpG Island Methylator Phenotype-Associated Factor That Predisposes Colon Cancer Cells to Irinotecan and Olaparib

Chemotherapy is a mainstay of colorectal cancer treatment, and often involves a combination drug regime. CpG island methylator phenotype (CIMP)-positive tumors are potentially more responsive to the topoisomerase-inhibitor irinotecan. The mechanistic basis of the increased sensitivity of CIMP cancer...

Full description

Bibliographic Details
Main Authors: Zeenat Jahan, Fahad A. Benthani, Nicola Currey, Hannah W. Parker, Jane E. Dahlstrom, C. Elizabeth Caldon, Maija R. J. Kohonen-Corish
Format: Article
Language:English
Published: MDPI AG 2022-06-01
Series:Cancers
Subjects:
colorectal cancer
precision medicine
epigenetic biomarker
mutated in colorectal cancer (MCC)
CIMP
Online Access:https://www.mdpi.com/2072-6694/14/12/2859

Internet

https://www.mdpi.com/2072-6694/14/12/2859

Similar Items